Skip to main content

Haemonetics Corp

HAE
Exchange
NYSE
Industry
Surgical & Medical Instruments & Apparatus
SEC CIK
0000313143

In the last 90 days, Haemonetics Corp insiders filed 0 open-market purchases and 1 sale; 357 institutions reported holding it in 13F filings for Q3 2026, worth $5.11B in total; no superinvestor holds it.

Currency
USD
Source
SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
Updated
Nov 8, 2026, 10:30 PM ET

Revenue flow, FY2026

Where the revenue went in FY2026, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.

Income statement

Each column is one fiscal year, newest first.

Income statement of Haemonetics Corp, annual
Line itemFY2026FY2025FY2024FY2023FY2022
Period endMar 28, 2026Mar 29, 2025Mar 30, 2024Apr 1, 2023Apr 2, 2022
Filing10-K10-K10-K10-K10-K
ReportedMay 7, 2026May 8, 2025May 9, 2024May 11, 2023May 10, 2022
Revenue$1.33B$1.36B$1.31B$1.17B$993.2M
Cost of revenue$546.4M$611.9M$617.5M$553.6M$487.7M
Gross profit$787.6M$749.0M$691.5M$615.1M$505.5M
Operating expenses$630.9M$527.1M$526.7M$459.1M$424.8M
Research and development$59.8M$62.7M$54.4M$50.1M$46.8M
Selling, general and administrative$442.4M$436.8M$431.8M$376.7M$339.6M
Operating income$156.7M$221.8M$164.9M$156.0M$80.8M
Interest expense$19.3M$35.9M$19.5M$13.0M$5.80M
Income tax$30.7M$44.4M$34.3M$26.0M$20.3M
Net income$97.3M$167.7M$117.6M$115.4M$43.4M
EPS, basic$2.06$3.33$2.32$2.27$0.85
EPS, diluted$2.05$3.31$2.29$2.24$0.84
Weighted shares, basic47.2M50.3M50.7M50.8M51.0M
Weighted shares, diluted47.4M50.7M51.4M51.4M51.4M
Margins and growth
Gross margin59.0%55.0%52.8%52.6%50.9%
Operating margin11.7%16.3%12.6%13.4%8.1%
Net margin7.3%12.3%9.0%9.9%4.4%
Revenue growth, year over year−2.0%+4.0%+12.0%+17.7%+14.1%
Net income growth, year over year−42.0%+42.6%+1.9%+166.1%−45.4%

Balance sheet

Each column is one fiscal year, newest first.

Balance sheet of Haemonetics Corp, annual
Line itemFY2026FY2025FY2024FY2023FY2022
Period endMar 28, 2026Mar 29, 2025Mar 30, 2024Apr 1, 2023Apr 2, 2022
Filing10-K10-K10-K10-K10-K
ReportedMay 7, 2026May 8, 2025May 9, 2024May 11, 2023May 10, 2022
Cash and equivalents$245.4M$306.8M$178.8M$284.5M$259.5M
Accounts receivable$216.9M$202.7M$206.6M$179.1M$159.4M
Inventory$306.4M$365.1M$317.2M$259.4M$293.0M
Total current assets$834.9M$935.0M$768.9M$769.7M$756.0M
Property, plant and equipment$305.8M$284.1M$311.4M$310.9M$258.5M
Goodwill$656.4M$604.3M$565.1M$466.2M$467.3M
Intangible assets$447.7M$455.7M$406.1M$275.8M$310.3M
Total assets$2.40B$2.45B$2.20B$1.93B$1.86B
Accounts payable$51.1M$67.0M$73.4M$63.9M$58.4M
Short-term debt$5.01M$303.6M$10.2M$11.8M$214.1M
Total current liabilities$282.6M$578.1M$300.4M$251.8M$442.3M
Long-term debt$1.22B$921.2M$797.6M$754.1M$559.4M
Shareholders' equity$796.3M$820.8M$960.0M$818.0M$749.4M

Cash flow statement

Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.

Cash flow statement of Haemonetics Corp, annual
Line itemFY2026FY2025FY2024FY2023FY2022
Period endMar 28, 2026Mar 29, 2025Mar 30, 2024Apr 1, 2023Apr 2, 2022
Filing10-K10-K10-K10-K10-K
ReportedMay 7, 2026May 8, 2025May 9, 2024May 11, 2023May 10, 2022
Operating cash flow$293.2M$181.7M$181.8M$273.1M$172.3M
Capital expenditures$32.8M$39.3M$66.3M$110.2M$96.5M
Free cash flow$260.4M$142.4M$115.5M$162.9M$75.8M
Depreciation and amortization$111.7M$115.6M$97.2M$93.3M$97.7M
Stock-based compensation$33.8M$29.6M$28.3M$25.6M$24.4M
Share buybacks$175.0M$225.0M$0$75.0M$0
Investing cash flow-$179.5M-$161.9M-$322.4M-$143.8M-$86.3M
Financing cash flow-$178.5M$108.8M$38.2M-$100.4M-$15.7M
Net change in cash-$61.3M$128.0M-$105.7M$25.0M$67.2M
Ratio
Stock-based compensation, % of revenue2.5%2.2%2.2%2.2%2.5%

Shares outstanding

Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.

Shares outstanding for Haemonetics Corp by cover date
Cover dateShares outstandingChange in a yearFiling
Oct 30, 202645.5M−2.7%SEC
Jul 31, 202645.5M−5.6%SEC
May 15, 202645.4M−5.4%SEC
Jan 30, 202646.5M−7.5%SEC
Oct 31, 202546.8M−6.8%SEC
Aug 1, 202548.2M−5.9%SEC
May 16, 202548.0M−5.5%SEC
Feb 3, 202550.2M−1.1%SEC

Notes and known gaps

How these numbers are put together, and what they can't tell you.

  • Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
  • Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.

Known gaps

  • Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
  • EPS and share counts are as reported at the time, not adjusted for later stock splits.
  • For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
  • For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
  • Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
  • Depreciation and amortization is missing for some companies that report it under their own XBRL tags.